Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has raised $12.7 million in an oversubscribed Series C-1 financing round led by River Cities Capital Funds (River Cities).

“This funding will be instrumental in fueling rapid growth for Catalyst through increased inventory, expanded distribution and new product development,” said Brian K. Hutchison, Catalyst chairman and CEO. “The additional funding will allow us to enhance company infrastructure and hire additional talent to support our growth and to bring our novel approach to total shoulder arthroplasty to surgeons and their patients.”

“We are excited to partner with Catalyst to fuel the growth of the company and advance minimally invasive surgery in shoulder arthroplasty,” said Carter McNabb, managing director at River Cities, who will join Catalyst’s board of directors.

Designed by surgeons for surgeons, the Catalyst CSR™ Total Shoulder System is a disruptive technology that represents the next evolution in shoulder surgery. The simple surgical technique creates a unique, multiplanar chamfer cut on the humeral head that minimizes bone removal and preserves the strongest, densest bone for the humeral component fixation – similar to modern knee replacement. Patented, angled glenoid instruments aid in the glenoid exposure and lessen retraction on the soft tissue. The precision of the system’s implants and instrumentation yields highly accurate and repeatable restoration of the native non-spherical anatomy. These benefits position the Catalyst CSR system as an attractive solution for anatomic total shoulder replacement surgery.

Today, the Catalyst CSR system has been used in more than 1,000 surgeries. The first patients are more than two years post surgery with excellent clinical results. The system has seen rapid adoption and is supported by a team of top key opinion leaders in the shoulder replacement market.

England Securities LLC acted as financial advisor and Dentons US LLP acted as legal advisor for Catalyst in the transaction.

We are looking forward to the October 7 episode of Grey’s Anatomy that features Simbionix simulators from Surgical Science. More on the GI Mentor: https://t.co/fAkg5l9rbo
#Simbionix #GreysAnatomy #endoscopy #simulation #medicalsimulation #MedEd

The Competition Module on the recently unveiled ENDO Mentor Suite https://t.co/ZxSu7GBMmx was well received at SAGES. "The simulator was really fun to use and had me using the same techniques I’ve been trained to use on real patients!" said competition winner, Nicholas Rawson, DO

Is your organization thinking about deploying #smartphones for #nurses? Stop✋🏽what you're doing and read our blog to get some key insights about mobilizing care team communication by selecting the right #mobiledevices for nurses.📱More here: https://t.co/JB6yOZ57DY

We are #hiring a VP of Americas Enterprise Sales who will own the go-to-market organization (GTM) for our Enterprise portfolio for both direct and indirect sales motions. Click below to learn more & apply today! https://t.co/za5X2cksrS

Accurate tissue diagnosis improves therapeutics and patient outcomes. With NICO’s intra- operative tissue collection and biological preservation, more in-tact and viable tissue is collected. #niconeurosurgery #neurosolutions

Our Integrated System - NICO Corporation

NICO technologies are part of an integrated systems solution to ACCESS, ILLUMINATE, REMOVE, COLLECT and PRESERVE that address unmet needs of the neuro...

ow.ly